Diagnostic Value and Prognostic Significance of Pleural C-Reactive Protein in Lung Cancer Patients with Malignant Pleural Effusions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: C-reactive protein (CRP) has been implicated in various inflammatory and advanced malignant states. Increased serum CRP (s-CRP) levels have been shown to be associated with independent prognostic factors for survival in patients with advanced lung cancer. However, only few studies have focused on the role of CRP in pleural effusions. This study aimed to evaluate the diagnostic and prognostic value of pleural CRP (p-CRP) in lung cancer patients with malignant pleural effusion (MPE). Materials and Methods: Pleural effusion (PE) samples were collected from patients with MPE (68 lung cancers; 12 extrathoracic tumors), and from 68 patients with various benign conditions (31 with pneumonia; 37 with tuberculosis). Concentrations of p- and s-CRP were measured by enzyme-linked immunosorbent assay. CRP level in pleural fluid and its association with survival were examined. Results: p-CRP levels correlated with s-CRP levels (r=0.82, p<0.0001). For the differential diagnosis of MPE and benign PE, the area under the receiver operating characteristic curve was greater for p-CRP (0.86) than for s-CRP (0.77). High p-CRP expression significantly correlated with shorter overall survival (p=0.006). P-CRP was independent prognostic factor significantly associated with overall survival on multivariated analysis (p=0.0001). The relative risk of death for lung cancer patients with high p-CRP levels was 3.909 (95% confidence interval, 2.000-7.639). Conclusion: P-CRP is superior to s-CRP in determining pleural fluid etiology. Quantitative measurement of p-CRP might be a useful complementary diagnostic and prognostic test for lung cancer patients with MPE.
Abstract
Purpose: C-reactive protein (CRP) has been implicated in various inflammatory and advanced malignant states. Increased serum CRP (s-CRP) levels have been shown to be associated with independent prognostic factors for survival in patients with advanced lung cancer. However, only few studies have focused on the role of CRP in pleural effusions. This study aimed to evaluate the diagnostic and prognostic value of pleural CRP (p-CRP) in lung cancer patients with malignant pleural effusion (MPE). Materials and Methods: Pleural effusion (PE) samples were collected from patients with MPE (68 lung cancers; 12 extrathoracic tumors), and from 68 patients with various benign conditions (31 with pneumonia; 37 with tuberculosis). Concentrations of p- and s-CRP were measured by enzyme-linked immunosorbent assay. CRP level in pleural fluid and its association with survival were examined. Results: p-CRP levels correlated with s-CRP levels (r=0.82, p<0.0001). For the differential diagnosis of MPE and benign PE, the area under the receiver operating characteristic curve was greater for p-CRP (0.86) than for s-CRP (0.77). High p-CRP expression significantly correlated with shorter overall survival (p=0.006). P-CRP was independent prognostic factor significantly associated with overall survival on multivariated analysis (p=0.0001). The relative risk of death for lung cancer patients with high p-CRP levels was 3.909 (95% confidence interval, 2.000-7.639). Conclusion: P-CRP is superior to s-CRP in determining pleural fluid etiology. Quantitative measurement of p-CRP might be a useful complementary diagnostic and prognostic test for lung cancer patients with MPE.
참고문헌 (35)
- Memon A, "Malignant effusions: diagnostic evaluation and therapeutic strategy", Curr Probl Cancer, 5, pp.1~30 (1981)
- Postmus PE, "The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer", J Thorac Oncol, 2, pp.686~693 (2007)
- Fiegl M, "Improving tumor cell detection in pleural effusions by interphase cytogenetics", Cytometry B Clin Cytom, 55, pp.60~62 (2003)
- Ferrer J, "Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions", Cancer, 86, pp.1488~1495 (1999)
- Miédougé M, "Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions", Br J Cancer, 81, pp.1059~1065 (1999)
- Gu P, "Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis", J Clin Lab Anal, 21, pp.398~405 (2007)
- 김혜진, "결핵성 및 악성흉수의 감별에 있어 흉수 내 TNF-α의 유용성", Tuberculosis and Respiratory Diseases, 59(6), pp.625~630 (2005), 대한결핵및호흡기학회
- Liang QL, "Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis", Thorax, 63, pp.35~41 (2008)
- Duffy MJ, "Role of tumor markers in patients with solid cancers: a critical review", Eur J Intern Med, 18, pp.175~184 (2007)
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)
- Mantovani A, "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)
- Chiang AC, "Molecular basis of metastasis", N Engl J Med, 359, pp.2814~2823 (2008)
- Mahmoud FA, "The role of C-reactive protein as a prognostic indicator in advanced cancer", Curr Oncol Rep, 4, pp.250~255 (2002)
- Pepys MB, "C-reactive protein: a critical update", J Clin Invest, 111, pp.1805~1812 (2003)
- Korppi M, "White blood cells, C-reactive protein and erythrocyte sedimentation rate in pneumococcal pneumonia in children", Eur Respir J, 10, pp.1125~1129 (1997)
- Smith RP, "C-reactive protein in simple community-acquired pneumonia", Chest, 107, pp.1028~1031 (1995)
- Castaño Vidriales JL, "Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions", Eur J Med, 1, pp.201~207 (1992)
- Yilmaz Turay U, "Use of pleural fluid C-reactive protein in diagnosis of pleural effusions", Respir Med, 94, pp.432~435 (2000)
- Hara M, "Preoperative serum C-reactive protein level in non-small cell lung cancer", Anticancer Res, 27, pp.3001~3004 (2007)
- Pelliniemi TT, "Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group", Blood, 85, pp.765~771 (1995)
- Jabs WJ, "Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue", Kidney Int, 68, pp.2103~2110 (2005)
- Nozoe T, "Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer", Am J Surg, 176, pp.335~338 (1998)
- Hefler LA, "Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer", Clin Cancer Res, 14, pp.710~714 (2008)
- Hashimoto K, "The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma", Cancer, 103, pp.1856~1864 (2005)
- Light RW, "Diagnostic principles in pleural disease", Eur Respir J, 10, pp.476~481 (1997)
- Papageorgiou E, "Increased oxidative stress in exudative pleural effusions: a new marker for the differentiation between exudates and transudates?", Chest, 128, pp.3291~3297 (2005)
- Chierakul N, "A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion", Respirology, 9, pp.66~69 (2004)
- 김대용, "The Usefulness of Procalcitonin and C-Reactive Protein as Early Diagnostic Markers of Bacteremia in Cancer Patients with Febrile Neutropenia", Cancer Research and Treatment, 43(3), pp.176~180 (2011), 대한암학회
- Botana-Rial M, "Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion", Clin Lab, 57, pp.373~378 (2011)
- Heikkilä K, "A systematic review of the association between circulating concentrations of C reactive protein and cancer", J Epidemiol Community Health, 61, pp.824~833 (2007)
- Scott HR, "The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer", Br J Cancer, 87, pp.264~267 (2002)
- Søyseth V, "The association between hospitalisation for pneumonia and the diagnosis of lung cancer", Lung Cancer, 57, pp.152~158 (2007)
- Brundage MD, "Prognostic factors in non-small cell lung cancer: a decade of progress", Chest, 122, pp.1037~1057 (2002)
- Forrest LM, "Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer", Br J Cancer, 89, pp.1028~1030 (2003)
- O’Dowd C, "Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer", J Thorac Oncol, 5, pp.988~992 (2010)